Source: http://www.google.com/patents/US8071641?dq=5343970
Timestamp: 2014-09-15 05:27:45
Document Index: 503808812

Matched Legal Cases: ['Application No. 160420', 'Application No. 05703237', 'Application No. 05703237', 'Application No. 160420', 'Application No. 160420', 'Application No. 05703237', 'Application No. 05703237']

Patent US8071641 - Treating or preventing diabetes with cannabidiol - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign in<nobr>Advanced Patent Search</nobr>PatentsUse of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis....http://www.google.com/patents/US8071641?utm_source=gb-gplus-sharePatent US8071641 - Treating or preventing diabetes with cannabidiolAdvanced Patent SearchPublication numberUS8071641 B2Publication typeGrantApplication numberUS 10/589,623PCT numberPCT/IL2005/000196Publication dateDec 6, 2011Filing dateFeb 16, 2005Priority dateFeb 16, 2004Also published asEP1720535A1, EP1720535B1, US20070099987, WO2005077348A1Publication number10589623, 589623, PCT/2005/196, PCT/IL/2005/000196, PCT/IL/2005/00196, PCT/IL/5/000196, PCT/IL/5/00196, PCT/IL2005/000196, PCT/IL2005/00196, PCT/IL2005000196, PCT/IL200500196, PCT/IL5/000196, PCT/IL5/00196, PCT/IL5000196, PCT/IL500196, US 8071641 B2, US 8071641B2, US-B2-8071641, US8071641 B2, US8071641B2InventorsLola Weiss, Michael Zeira, Raphael Mechoulam, Shimon Slavin, Ruth GallilyOriginal AssigneeYissum Research Development Company Of The Hebrew University Of Jerusalem, Hadsit Hadasit Medical Research Services and Development Ltd.Export CitationBiBTeX, EndNote, RefManPatent Citations (22), Non-Patent Citations (55), Classifications (11), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetTreating or preventing diabetes with cannabidiolUS 8071641 B2Abstract Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.
RELATED APPLICATIONS This application is a National Phase Application of PCT Patent Application No. PCT/IL2005/000196 having International Filing Date of Feb. 16, 2005, which claims the benefit of Israel Application No. 160420 filed on Feb. 16, 2004. The contents of the above Applications are all incorporated herein by reference.
FIELD AND BACKGROUND OF THE INVENTION The present invention relates to the use of a cannabidiol for treating or preventing diabetes and related disorders.
SUMMARY OF THE INVENTION According to one aspect of the present invention there is provided use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes.
R″ is selected from the group consisting of a straight or branched alkyl having 5 to 12 carbon atoms; an �OR′″, where R′″ is straight or branched alkyl having 5 to 9 carbon atoms, or a straight or branched alkyl substituted at the terminal carbon atom by a phenyl group; and a �(CH2)n�O-alkyl group, where n is an integer from 1 to 7 and the alkyl group has 1 to 5 carbon atoms.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention is of a method of treating or preventing diabetes and via administration of a cannabidiol. The present invention is further of an article-of-manufacturing which includes a cannabidiol and is identified for use in treatment or prevention of diabetes and related disorders.
As used herein, the phrases �treating or preventing� and �treatment or prevention� encompass the complete range of therapeutically positive effects of administrating a cannabidiol to a subject including reduction of, alleviation of, and relief from, diabetes and illness, diabetes symptoms or diabetes related disorders. Treatment or prevention includes the prevention or postponement of development of the disease, prevention or postponement of development of symptoms such as, for example, hyperglycemia or glucosuria and/or a reduction in the severity of such symptoms that will or are expected to develop. These further include ameliorating existing symptoms, preventing additional symptoms and ameliorating or preventing the underlying metabolic causes of symptoms.
The phrase �prolong survival� refers to prolonging viability and biological function (e.g., insulin secretion) of the transplanted pancreatic cells.
The phrase �pancreatic cells� used herein refers to a whole or partially intact pancreas, pancreatic Langerhans islets, or isolated pancreatic cells. The cells may be autograft cells, allograft cells, xenograft cells, differentiated stem cells, or residual cells.
The term �cannabinoid� refers to any natural or synthetic agonist of a cannabinoid receptor (e.g., CB1 and CB2). Naturally occurring cannabinoids may be divided into two categories, plant-derived and endogenous. Plant-derived cannabinoids are exemplified by the well-known Δ9-tetrahydrocannabinol (THC), the psychotropic principle in marijuana. Endogenous cannabinoids (endocannabinoids) are a class of lipid-like molecules that share receptor binding sites with plant-derived cannabinoids and mimic many of their neurobehavioral effects [Mechoulam et al., Adv. Exp. Bio. Med. 402:95-101 (1996)]. Two endocannabinoids have been characterized in some detail: arachidonyl ethanolamide (anandamide) [Devane et al., Science 258:1946-1949 (1992); Felder et al., Proc. Natl. Acad. Sci. USA. 90:7656-7660 (1993)] and 2-arachidonoyl glycerol (2-AG) [Mechoulam et al., Biochem. Pharmacol 50:83-90 (1995)].
Further additional natural or synthetic cannabinoids are described in U.S. Pat. Nos. 4,371,720, 5,013,387, 5,081,122, 5,292,736, 5,461,034, 5,618,955, 6,166,066 and 6,531,636; International Patent applications WO 01/9773, WO 97/29079, WO 99/02499, WO 98/41519, and WO 94/12466; European Patent Nos. EP 0570920 and EP 0444451; French Patent No. FR 2735774; and Israeli Pat. Nos. IL 01/00551 and IL 99/00187; Gaoni and Mechoulam, J. Amer. Chem. Soc. 93, 217 (1971); Mechoulam et al., Science 169, 611 (1970); Edery et al., Ann. N.Y. Acad. Sci., 191,40 (1971); Mechoulam et al., J. Amer. Chem. Soc., 94,7930 (1972); R. Mechoulam (ed.), �Marijuana: Chemistry, Metabolism, Pharmacology, and Clinical Effects� Academic Press, 1973, New-York; Houry et al., J. Med. Chem., 17, 287 (1974); Houry et al., J. Med. Chem., 18, 951 (1975); Mechoulam et al., Chem. Reviews, 76,75 (1976); Mechoulam et al., J. Med. Chem., 23, 1068 (1980); Srebnik et al., J. Chem. Soc., Perkin Trans. I, 2881 (1984); Mechoulam et al., Tetrahedron: Asymmetry, 1, 315 (1990); Devane et al., Science, 258,1946 (1992); Burstein et al., J. Med. Chem., 35, 3135 (1992); Hanus et al., J. Med. Chem., 36, 3032 (1993); Mechoulam et al., Biochem. Pharmacol., 50, 83 (1995); Sheskin et al., J. Med. Chem., 40, 659 (1997); Rhee et al., J. Med. Chem. 40, 3228 (1997); and Hanus et al., PNAS, 98, 3662 (2001).
Unlike cannabinoids such as described hereinabove, cannabidiol does not bind either the brain receptor CB1 or the peripheral receptors CB2 and therefore does not cause the central or peripheral effects mediated by these receptors. Furthermore, CBD has no psychotropic (cannabimimetic) activity and its molecular structure and properties are substantially different from those of cannabinoids [Science 169: 611-612 (1970); �Marijuana/cannabinoids: neurobiology and neurophysiology�, ed. L. Murphy and A. Bartke, CRC Press, Boca Raton, 1-33 (1992)].
a. straight or branched alkyl of 5 to 12 carbon atoms; b. a group �O�R′″, where R′″ is straight or branched alkyl of 5 to 9 carbon atoms, or a straight or branched alkyl substituted at the terminal carbon atom by a phenyl group; or c. a group �(CH2)n�O-alkyl, where n is an integer from 1 to 7 and the alkyl group contains 1 to 5 carbon atoms. According to one preferred embodiment of the present invention, the cannabidiol is a natural cannabidiol having formula I described above, wherein R′=CH3 and R″=C5H11 A natural cannabidiol can be extracted from Cannabis using methods such as described, for example, in U.S. Pat. No. 6,403,123 and Gaoni and Mechoulam [J. Am. Chem. Soc. 93: 217-224 (1971)].
b. a group �O�R′″, where R′″ is straight or branched alkyl of 5 to 9 carbon atoms, or a straight or branched alkyl substituted at the terminal carbon atom by a phenyl group; or
c. a group �(CH2)n�O-alkyl, where n is an integer from 1 to 7 and the alkyl group contains 1 to 5 carbon atoms.
For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. As used herein, the term �oral administration� includes administration of the pharmaceutical compound to any oral surface, including the tongue, gums, palate, or other buccal surfaces. Addition methods of oral administration include provision of the pharmaceutical composition in a mist, spray or suspension compatible with tissues of the oral surface.
Example 1 Preventing Diabetes in NOD Mice by Administering Cannabidiol Materials and Methods:
INFγ (pg/ml)1 � SD
107 � 41
94 � 41
43 � 21*2 1Each value represents a mean of 5 mice (replications).
Example 2 Cannabidiol Suppressing diabetes in male NOD mice induced with the disease Animals�See Example 1, Above.
Experimental design�Male NOD mice were irradiated (650 cGy), 24 hrs prior to intravenous injection of spleen cells (25-28�106) derived from female diabetic mice. The injected mice were divided into three groups including untreated control; vehicle treated mice (20 IP injections, 5 times/week); and CBD treated mice (5 mg/kg CBD, 20 IP injections, 5 times/week).
Intraperitoneal glucose tolerance tests (IPGTT)�see Example 1 above. Blood glucose levels above 140 mg/dl were considered diabetic by testing blood glucose at t-0, 60 min following IP injection of 1 gr/Kg body weight of glucose [Glucometer Elite apparatus (Bayer Diagnostics, ELKART, IN)]. Alternatively, urine samples were taken twice a week from diabetic mice for testing glucose levels. Urine glucose levels above 1000 mg/dl as determined by combi 9 Teststrips (Medi-Test, Macherey-Nagel, Duren, Germany) were considered diabetic;
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4371720Jul 28, 1981Feb 1, 1983Pfizer Inc.Antidiarrheals, antiemeticsUS5013387Apr 10, 1990May 7, 1991Monarch Marking Systems, Inc.Hand-held labellerUS5081122Mar 5, 1990Jan 14, 1992Sterling Drug Inc.Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereofUS5292736Feb 26, 1993Mar 8, 1994Sterling Winthrop Inc.Morpholinoalkylindenes as antiglaucoma agentsUS5461034Jun 18, 1993Oct 24, 1995Yissum Research Development Company Of The Hebrew University Of JerusalemOsteogenic growth polypeptides identified from regenerating bone marrowUS5618955Nov 30, 1993Apr 8, 1997Yissum Research Development Company Of The Hebrew University Of JerusalemAntiinflammatory agents, analgesicsUS6166066May 4, 1999Dec 26, 2000The University Of ConnecticutCannabinoids selective for the CB2 receptorUS6403123Sep 19, 2000Jun 11, 2002Eugene J. Van ScottTopical application of anthralin that results in minimal or no staining of skin or clothing; applying a wax formulation over the involved areaUS6410588Apr 14, 1999Jun 25, 2002The Mathilda And Terence Kennedy Institute Of RheumatologyUse of cannabinoids as anti-inflammatory agentsUS6531636Oct 3, 2000Mar 11, 2003Yissum Research Development Company Of The Hebrew University Of JerusalemDerivatives of 2-archidonoyl glycerol, stable to hydrolysis; ethers derived from long chain fatty alcohols (archidonyl alcohol) bind to the CB1 and CB2 cannabinoid receptors; in vivo effects similar to anandamide and 2-Ara-GlUS7071231 *Sep 6, 2002Jul 4, 2006Telik, Inc.Especially Type II diabetes; stimulating the kinase activity of the insulin receptor; activating the insulin receptorEP0444451A2Feb 7, 1991Sep 4, 1991Sterling Winthrop Inc.3-Arylcarbonyl-1H-indoles useful as therapeutic agentsEP0570920A1May 18, 1993Nov 24, 1993Yissum Research And Development Company Of The Hebrew University Of JerusalemProbe for cannabinoid receptorsFR2735774A1 Title not availableWO1994012466A1Nov 30, 1993Jun 9, 1994Aviva BeuerFatty acid derivatives and pharmaceutical compositions containing themWO1997029079A1Feb 6, 1997Aug 14, 1997Takashi InabaNovel compounds and pharmaceutical use thereofWO1998041519A1Mar 18, 1998Sep 24, 1998Paul Elliot BenderNovel cannabinoid receptor agonistsWO1999002499A1Jul 9, 1998Jan 21, 1999Takashi InabaQuinoline compounds and medicinal uses thereofWO1999053917A1Apr 21, 1999Oct 28, 1999Julius AxelrodCannabinoids as antioxidants and neuroprotectantsWO2000019773A1Sep 24, 1999Apr 6, 2000Arthur GurevichMulti-conductor soft heating elementWO2002013814A1 *Aug 9, 2001Feb 21, 2002Hill David JCompositions and methods for inhibiting islet dysfunction and autoimmune disordersWO2003063847A1Feb 3, 2003Aug 7, 2003Gw Pharma LtdCompositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions* Cited by examinerNon-Patent CitationsReference1??? "Cannabis-Based Medicines-GW Pharmaceuticals: High CBD, High THC, Medicinal Cannabis-GW Pharmaceuticals, THC: CBD", Drugs R&D, 4(5): 306-309, 2003. p. 307, 4th Full �.2??? "Cannabis-Based Medicines�GW Pharmaceuticals: High CBD, High THC, Medicinal Cannabis�GW Pharmaceuticals, THC: CBD", Drugs R&D, 4(5): 306-309, 2003. p. 307, 4th Full �.3Adams et al. "Isolation of Cannabinol, Cannabidiol and Quebrachitol From Red Oil of Minnesota Wild Hemp", Journal of the American Chemical Society, 62: 2194-2196, 1940.4Adis "Cannabis-Based Medicines-GW Pharmaceuticals. High CBD, High THC, Medicinal Cannabis-GW Pharmaceuticals, THC:CBD", Drugs R & D, 4(5): 306-309, 2003.5Adis "Cannabis-Based Medicines�GW Pharmaceuticals. High CBD, High THC, Medicinal Cannabis�GW Pharmaceuticals, THC:CBD", Drugs R & D, 4(5): 306-309, 2003.6Burstein et al. "Synthetic Nonpsychotropic Cannabinoids With Potent Antiinflammatory, Analgesic, and Leukocyte Antiadhesion Activities", Journal of Medicinal Chemistry, 35: 3135-3141, 1992.7Coffey et al. "Tetrahydrocannabinol Inhibition of Macrophage Nitric Oxide Production", Biochemical Pharmacology, 52: 743-751, 1996.8Communication Pursuant to Article 94(3) EPC Dated Dec. 18, 2009 From the European Patent Office Re.: Application No. 05703237.7.9Communication Pursuant to Article 94(3) EPC Dated Nov. 29, 2010 From the European Patent Office Re.: Application No. 05703237.7.10Devane et al. "Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor", Science, 258: 1946-1949, 1992.11Edery et al. "Structural Requirements for Cannabinoid Activity", Annals of the NY Academy of Sciences, 191: 40-53, 1971.12Felder et al. "Anandamide, An Endogenous Cannabimimetic Eicosanoid, Binds to the Cloned Human Cannabinoid Receptor and Stimulates Receptor-Mediated Signal Transduction", Proc. Natl. Acad. Sci. USA, 90: 7656-7660, 1993.13Formukong et al. "Analgesic and Antiflammatory Activity of Constituents of Cannabis Sativa L.", Inflammation, 12(4): 361-371, 1988.14Gaoni et al. "The Isolation and Structure of Delta1-Tetrahydrocannabinol and Other Neutral Cannbinoids From Hashish", Journal of the American Chemical Society, 93: 217-224, 1971.15Gaoni et al. "The Isolation and Structure of Δ1�Tetrahydrocannabinol and Other Neutral Cannbinoids From Hashish", Journal of the American Chemical Society, 93: 217-224, 1971.16 *Gorter Cancer cachexia and cannabinoids. Forschende Komplementarmedizin, 1999 vol. 6, No. Suppl. 3, pp. 21-22. ISSN: 1021-7096.17Hanu{hacek over (s)} et al. "2-Arachidonyl Glyceryl Ether, An Endogenous Agonsit of the Cannabinoid CBI Receptor", Proc. Natl. Acad. Sci. USA, 98(7): 3662-3665, 2001.18Hanu{hacek over (s)} et al. "Two New Unsaturated Fatty Acid Ethanolamides in Brain That Bind to the Cannabinoid Receptor", Journal of Medicinal Chemistry, 36: 3032-3034, 1993.19Houry et al. "Benzoxocin and Bensoxonin Derivatives. Novel Groups of Terpenophenols With Central Nervous System Activity. A Correction", Journal of Medicinal Chemistry, 18(9): 951-952, 1975.20Houry et al. "Benzoxocin and Benzoxonin Derivatives. Novel Groups of Terpenophenols With Central Nervous System Activity", Journal of Medicinal Chemistry, 17(3): 287-293, 1974.21International Search Report and the Written Opinion Dated Jun. 21, 2005 From the International Searching Authority Re.: Application No. PCT/IL2005/000196.22Kendall et al. "Pancreas and Islet Transplantation", The Endocrinologist, 5: 28-35, 1995.23Leite et al. "Anticonvulsant Effects of the (-) and (+)Isomers of Cannabidiol and Their Dimethylheptyl Homologs", Pharmacology, 24: 141-146, 1982.24Leite et al. "Anticonvulsant Effects of the (−) and (+)Isomers of Cannabidiol and Their Dimethylheptyl Homologs", Pharmacology, 24: 141-146, 1982.25Mechoulam "Marijuana: Chemistry, Pharmacology, Metabolism and Clinical Effects", Academic Press, 65: Book Info & Table of Contents, 1973.26Mechoulam et al. "A Total Synthesis of D1-Delta1-Tetrahydrocannabinol, the Active Constituent of Hashish", Journal of the American Chemical Society, 87(14): 3273-3275, 1965.27Mechoulam et al. "Chemical Basis of Hashish Activity", Science, 169(3945): 611-612, 1970.28Mechoulam et al. "Hashish-I. The Structure of Cannabidiol", Tetrahedron, 19: 2073-2078, 1963.29Mechoulam et al. "Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors", Biochemical Pharmacology, 50(1): 83-90, 1995.30Mechoulam et al. "Recent Advances in the Chemistry and Biochemistry of Cannabis", Chemical Reviews, 76(1): 75-112, 1976.31Mechoulam et al. "Stereochemical Requirements for Cannabinoid Activity", Journal of Medicinal Chemistry, 23(10): 1068-1072, 1980.32Mechoulam et al. "Synthesis and Biological Activity of Five Tetrahydrocannabinol Metabolites", Journal of the American Chemical Society, 94(22): 7930-7931, 1972.33Mechoulam et al. "Synthesis of the Indivivdual, Pharmacologically Distinct, Enantiomers of A Tetrahydrocannabinol Derivative", Tetrahedron: Asymmetry, 1(5): 315-318, 1990.34Mechoulam et al. "A Total Synthesis of D1-Δ1�Tetrahydrocannabinol, the Active Constituent of Hashish", Journal of the American Chemical Society, 87(14): 3273-3275, 1965.35Mechoulam et al. "Hashish�I. The Structure of Cannabidiol", Tetrahedron, 19: 2073-2078, 1963.36Murphy et al. "Cannabinoid Geometry and Biological Activity", Marijuana/Cannbinoids: Neurobiology and Neurophysiology, p. 1-33, 1992.37Office Action Dated Feb. 1, 2010 From the Israel Patent Office Re.: Application No. 160420 and Its Translation Into English.38Office Action Dated Feb. 11, 2009 From the Israeli Patent Office Re.: Application No. 160420 and Its Translation Into English.39Official Action Dated Feb. 16, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/589,623.40Petrzilka et al. "Synthese und Chiralit�t des (-)-Cannabidiols", Helvetica Chimica Acta, 50, Fasciculus 2(73-74/Chap.74): 719-723, 1967.41Petrzilka et al. "Synthese und Chiralit�t des (−)-Cannabidiols", Helvetica Chimica Acta, 50, Fasciculus 2(73-74/Chap.74): 719-723, 1967.42Response Dated May 22, 2011 to Communication Pursuant to Article 94(3) EPC of Nov. 29, 2010 From the European Patent Office Re.: Application No. 05703237.7.43Response Dated Sep. 27, 2010 to Communication Pursuant to Article 94(3) EPC of Dec. 18, 2009 From the European Patent Office Re.: Application No. 05703237.7.44Rhee et al. "Cannabinol Derivatives: Binding to Cannabinoid Receptors and Inhibiton of Adenylylcyclase", Journal of Medicinal Chemistry, 40: 3228-3233, 1997.45Robertson "Seminars in Medicine of the Beth Israel Hospital, Boston: Pancreatic and Islet Transplantation for Diabetes-Cures of Curiosities?", The New England Journal of Medicine, 327(26): 1861-1868.46Robertson "Seminars in Medicine of the Beth Israel Hospital, Boston: Pancreatic and Islet Transplantation for Diabetes�Cures of Curiosities?", The New England Journal of Medicine, 327(26): 1861-1868.47Sheskin et al. "Structural Requirements for Binding of Anandamide-Type Compounds to the Brain Cannabinoid Receptor", Journal of Mrdicinal Chemistry, 40: 659-667, 1997.48Srebnik et al. "Base-Catalysed Double-Bond Isomerizations of Cannabinoids: Structural and Stereochemical Aspects", Journal of the Chemical Society, Perkin Transactions I, p. 2881-2886, 1984.49Srivastava et al. "Delta9 Tetrahydrocannabinol and Cannabidiol Alter Cytokine Production by Human Immune Cells", Immunopharmacology, 40(3): 179-185, 1998. p. 183-184, � entitled "Discussion".50Srivastava et al. "Δ9 Tetrahydrocannabinol and Cannabidiol Alter Cytokine Production by Human Immune Cells", Immunopharmacology, 40(3): 179-185, 1998. p. 183-184, � entitled "Discussion".51Venstrom et al. "Survival After Pancreas Transplantation in Patients With Diabetes and Preserved Kidney Function", JAMA, 290(21): 2817-2823, 2003. Correction: 291(13); 1566, 2004.52Watzl et al. "Influence of Marijuana Components (THC and CBD) on Human Mononuclear Cell Cytokine Secretion in Vitro", Drugs of Abuse, Immunity, and Immunodeficiency, p. 63-70, 1991.53Weiss et al. "Cytokine Production in Linomide-Treated Nod Mice and the Potential Role of A Th1/Th2 Shift on Autoimmune and Anti-Inflammatory Processes", Cytokine, 19(2): 85-93, 2002. Fig.1, 4, p. 87-91, � entitled "Discussion".54Zuardi et al. "Antipsychotic Effect of Cannabidiol", Journal of Clinical Psychiatry, 56(10): 485-486, 1995.55Zuardi et al. "Effects of Cannabidiol in Animal Models Predictive of Antipsychotic Activity", Psychopharmacology, 104(2): 260-264, 1991.* Cited by examinerClassifications U.S. Classification514/454, 514/734, 514/568International ClassificationA61K31/05, A61K31/353, A61K31/192, A61K36/185Cooperative ClassificationA61K31/05, A61K36/185European ClassificationA61K31/05, A61K36/185Legal EventsDateCodeEventDescriptionApr 24, 2008ASAssignmentOwner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREWFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GALLILY, RUTH;MECHOULAM, RAPHAEL;REEL/FRAME:020847/0967Effective date: 20080326Feb 5, 2008ASAssignmentOwner name: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENTFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SLAVIN, SHIMON;WEISS, LOLA;ZEIRA, MICHAEL;REEL/FRAME:020463/0831;SIGNING DATES FROM 20060719 TO 20060723Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SLAVIN, SHIMON;WEISS, LOLA;ZEIRA, MICHAEL;SIGNING DATES FROM 20060719 TO 20060723;REEL/FRAME:020463/0831RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google